114 related articles for article (PubMed ID: 31876587)
21. Hepatitis C: an update on the silent epidemic.
Sarbah SA; Younossi ZM
J Clin Gastroenterol; 2000 Mar; 30(2):125-43. PubMed ID: 10730918
[TBL] [Abstract][Full Text] [Related]
22. Effect of preventive and curative interventions on hepatitis C virus transmission in Egypt (ANRS 1211): a modelling study.
Breban R; Arafa N; Leroy S; Mostafa A; Bakr I; Tondeur L; Abdel-Hamid M; Doss W; Esmat G; Mohamed MK; Fontanet A
Lancet Glob Health; 2014 Sep; 2(9):e541-e549. PubMed ID: 25304421
[TBL] [Abstract][Full Text] [Related]
23. The oncogenic hepatitis C virus and direct-acting antivirals: economic implications for hepatocellular carcinoma in Medicaid beneficiaries with cirrhosis.
Mantravadi S
Am J Manag Care; 2017 Apr; 23(5 Spec No.):SP180-SP184. PubMed ID: 28665676
[No Abstract] [Full Text] [Related]
24. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
[TBL] [Abstract][Full Text] [Related]
25. Should we treat acute hepatitis C? A decision and cost-effectiveness analysis.
Bethea ED; Chen Q; Hur C; Chung RT; Chhatwal J
Hepatology; 2018 Mar; 67(3):837-846. PubMed ID: 29059461
[TBL] [Abstract][Full Text] [Related]
26. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.
Seeff LB; Hoofnagle JH
Clin Liver Dis; 2003 Feb; 7(1):261-87. PubMed ID: 12691470
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of novel treatment of hepatitis C virus in Lebanese patients.
Nasser SC; Mansour H; Abi Nader T; Metni M
Int J Clin Pharm; 2018 Jun; 40(3):693-699. PubMed ID: 29611014
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
[TBL] [Abstract][Full Text] [Related]
29. Predicting the impact of adverse events and treatment duration on medical resource utilization-related costs in hepatitis C genotype 1 treatment-naïve patients receiving antiviral therapy.
Akpo EI; Cerri K; Kleintjens J
Pharmacoeconomics; 2015 Apr; 33(4):409-22. PubMed ID: 25577042
[TBL] [Abstract][Full Text] [Related]
30. The Opioid Epidemic in West Virginia.
Merino R; Bowden N; Katamneni S; Coustasse A
Health Care Manag (Frederick); 2019; 38(2):187-195. PubMed ID: 30920991
[TBL] [Abstract][Full Text] [Related]
31. Need of righteous attitudes towards eradication of hepatitis C virus infection in Latin America.
Panduro A; Roman S
World J Gastroenterol; 2016 Jun; 22(22):5137-42. PubMed ID: 27298556
[TBL] [Abstract][Full Text] [Related]
32. Assessing the burden of illness of chronic hepatitis C and impact of direct-acting antiviral use on healthcare costs in Medicaid.
Roebuck MC; Liberman JN
Am J Manag Care; 2019 Jun; 25(8 Suppl):S131-S139. PubMed ID: 31211526
[TBL] [Abstract][Full Text] [Related]
33. A Guide to the Economics of Hepatitis C Virus Cure in 2017.
Linas BP; Nolen S
Infect Dis Clin North Am; 2018 Jun; 32(2):447-459. PubMed ID: 29778265
[TBL] [Abstract][Full Text] [Related]
34. Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago.
Echevarria D; Gutfraind A; Boodram B; Layden J; Ozik J; Page K; Cotler SJ; Major M; Dahari H
Vaccine; 2019 May; 37(19):2608-2616. PubMed ID: 30962092
[TBL] [Abstract][Full Text] [Related]
35. [Prescription of new HCV-drugs - what has to be considered judicially].
Mauss S
Z Gastroenterol; 2015 Jan; 53(1):43-5. PubMed ID: 25594707
[TBL] [Abstract][Full Text] [Related]
36. Potential for public health success in tackling the hepatitis C virus epidemic.
Sheerin I
N Z Med J; 2017 Dec; 130(1467):73-77. PubMed ID: 29240743
[TBL] [Abstract][Full Text] [Related]
37. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
[TBL] [Abstract][Full Text] [Related]
38. Hepatitis C in Laos: A 7-Year Retrospective Study on 1765 Patients.
Paboriboune P; Vial T; Sitbounlang P; Bertani S; Trépo C; Dény P; Babin FX; Steenkeste N; Pineau P; Deharo E
Virol Sin; 2018 Aug; 33(4):295-303. PubMed ID: 29948850
[TBL] [Abstract][Full Text] [Related]
39. Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes.
Ruta S; Cernescu C
World J Gastroenterol; 2015 Oct; 21(38):10811-23. PubMed ID: 26478672
[TBL] [Abstract][Full Text] [Related]
40. The spectrum of chronic hepatitis C virus infection in the Virginia Correctional System: development of a strategy for the evaluation and treatment of inmates with HCV.
Sterling RK; Brown RS; Hofmann CM; Luketic VA; Stravitz RT; Sanyal AJ; Contos MJ; Mills AS; Smith V; Shiffman ML
Am J Gastroenterol; 2005 Feb; 100(2):313-21. PubMed ID: 15667488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
